LENZ Therapeutics, Inc. Stock OTC Markets
Equities
GRPH
US52635N1037
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 6.73M | Capitalization | 478M |
---|---|---|---|---|---|
Net income 2024 * | -52M | Net income 2025 * | -66M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 71 x |
P/E ratio 2024 * |
-6.68
x | P/E ratio 2025 * |
-7.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.17% |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - | |
0.00% | 32 M€ | +4.82% | - |
1st Jan change | Capi. | |
---|---|---|
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |